The purpose of this article was to study the association of human papillomavirus (HPV) with clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).Archival baseline tumor specimens were obtained from patients treated on two clinical trials in recurrent or metastatic SCCHN: E1395, a phase III trial of cisplatin and paclitaxel versus cisplatin and 5-fluorouracil, and E3301, a phase II trial of irinotecan and docetaxel. HPV DNA was detected by in situ hybridization (ISH) with a wide-spectrum probe. p16 status was evaluated by immunohistochemistry. Clinical outcomes of interest were objective response, progression-free survival (PFS) and overall survival (OS).We analyzed 64 patients for HPV ISH and 65 for p16. Eleven tumors (17

作者：A, Argiris；S, Li；M, Ghebremichael；A M, Egloff；L, Wang；A A, Forastiere；B, Burtness；R, Mehra

来源：Annals of oncology : official journal of the European Society for Medical Oncology 2014 年 25卷 7期